Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in “pre-launch inventory” in its financial statements, a filing showed on Wednesday.
Kevin T. Gade
Chief Operating Officer Principal & Portfolio Manager
[email protected]
Continue reading more HERE to hear insights from Bahl & Gaynor’s very own, Kevin Gade.